Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brivanib alaninate vs placebo plus cetuximab and irinotecan in K-RAS wild-type metastatic colorectal cancer
2007-005097-31Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metastatic colon cancer (mCRC) comparing Brivanib + cetuximab + irinotecan with Placebo + cetuximab + irinotecan (2 arms). Primary endpoints: Safety assessments (adverse events and clinical evaluations) and Incidence of thrombosis-related events (TREs). Started Jun 2008; status: completed.
02
Drugs
brivanib
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2007-005097-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005097-31.